-
Media ReleaseNovartis Cosentyx® sets the new benchmark in psoriasis with robust 5-year sustained efficacy and safety Phase III data
-
Media ReleaseMultimedia Assets Now Available: Novartis receives first ever FDA approval for a CAR-T cell therapy, Kymriah™ (tisagenlecleucel, CTL019), for children and young adults with B-cell ALL that is refractory or has relapsed at least twice
-
Media ReleaseNovartis receives first ever FDA approval for a CAR-T cell therapy, Kymriah™ (tisagenlecleucel, CTL019), for children and young adults with B-cell ALL that is refractory or has relapsed at least twice
-
Media ReleaseNovartis launches first large-scale research study in multiple sclerosis that allows participants to contribute from smartphones
-
Media ReleaseFDA Accepts Biologics License Application for AMG 334 (Erenumab), an Important Regulatory Milestone for Novartis
-
Media ReleaseNovartis confirms 5 year data for first and only fully-human IL-17A inhibitor Cosentyx® reinforcing sustained efficacy and safety profile in psoriasis
-
Media ReleaseNovartis pivotal CTL019 6-month follow-up data show durable remission rates in children, young adults with r/r B-cell ALL
-
Media ReleaseNovartis interim results from global, pivotal CTL019 trial show durable complete responses in adults with r/r DLBCL
-
Media ReleaseNovartis receives FDA approval for first-of-its-kind Kisqali® Femara® Co-Pack for initial treatment of HR+/HER2- advanced or metastatic breast cancer
-
Media ReleaseNovartis expands global collaboration with Amgen to commercialize first-in-class AMG 334 (erenumab) program in migraine prevention in the U.S. and Canada
-
Media ReleaseNovartis CAR-T cell therapy CTL019 receives FDA Breakthrough Therapy designation for treatment of adult patients with r/r DLBCL
-
Media ReleaseNovartis announces first CAR-T cell therapy BLA for pediatric and young adult patients with r/r B-cell ALL granted FDA Priority Review